Acute inflammation: endogenous cannabinoids mellow the harsh proinflammatory environment.

Area of Science:

• Immunology
• Gastroenterology
• Pharmacology

Background:

• Neutrophils infiltrate the intestinal mucosa during infection, aiding pathogen control but risking collateral damage.
• Resolving inflammation is crucial for limiting tissue injury and has therapeutic implications.
• Hepoxilin A3, an eicosanoid, attracts neutrophils to the gut lumen via the MRP2 efflux pump.

Purpose of the Study:

• To investigate the role of P-glycoprotein (P-gp) in regulating intestinal inflammation.
• To identify mechanisms by which endogenous compounds resolve inflammation.
• To explore the therapeutic potential of P-gp-mediated endocannabinoid secretion.

Main Methods:

• Investigated P-gp's function in secreting endocannabinoids into the intestinal lumen.
• Assessed the anti-inflammatory effects of P-gp-secreted endocannabinoids.
• Determined the role of cannabinoid receptor CB2 on neutrophils in mediating these effects.

Main Results:

• P-glycoprotein (P-gp) secretes endocannabinoids into the intestinal lumen.
• These endocannabinoids counteract the neutrophil-attracting effects of hepoxilin A3.
• The anti-inflammatory actions were mediated by the peripheral cannabinoid receptor CB2 on neutrophils.

Conclusions:

• P-gp-mediated endocannabinoid secretion is a key mechanism for resolving intestinal inflammation.
• This pathway involves counteracting pro-inflammatory eicosanoids like hepoxilin A3.
• Targeting this endogenous system offers potential therapeutic strategies for inflammatory conditions.